Bristol Myers Squibb names Cari Gallman as Executive Vice President, General Counsel and Chief Policy Officer Ruchika Sharma7 May 2025 11:15 AM ISTPrinceton: Bristol Myers Squibb has announced the appointment of Cari Gallman as Executive Vice President, General Counsel and Chief Policy...
USFDA updates Camzyos label to reduce echocardiography monitoring requirements, contraindications: Bristol Myers Squibb Ruchika Sharma18 April 2025 11:00 AM ISTPrinceton: Bristol Myers Squibb has announced that the U.S. Food and Drug Administration (FDA) has updated the U.S. Prescribing Information for...
Bristol Myers Squibb heart disease drug fails to meet main goals in late-stage study Ruchika Sharma16 April 2025 9:30 AM ISTPrinceton: Bristol Myers Squibb has announced the Phase 3 ODYSSEY-HCM trial evaluating Camzyos (mavacamten) for the treatment of adult...
Pomalyst monopoly case: Bristol Myers wins dismissal of lawsuit Ruchika Sharma13 April 2025 11:00 AM ISTA federal judge in New York has dismissed a proposed class action against pharmaceutical giant Bristol Myers Squibb, which accused the company of...
Bristol Myers Squibb receives positive EMA Committee opinion for Perioperative Opdivo plus Chemo in Resectable Non-Small Cell Lung Cancer plus PD-L1 Ruchika Sharma30 March 2025 12:15 PM ISTBristol Myers Squibb has announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has...
Bristol Myers Squibb to acquire 2seventy bio for USD 286 million Ruchika Sharma14 March 2025 12:30 PM ISTCambridge: 2seventy bio, Inc. has announced a definitive merger agreement under whichBristol Myers Squibb will acquire all of the...
Bristol Myers Squibb gets European Commission nod for Opdivo plus Yervoy for Hepatocellular Carcinoma Ruchika Sharma9 March 2025 12:30 PM ISTPrinceton: Bristol Myers Squibb has announced that the European Commission (EC) has approved Opdivo (nivolumab) plus Yervoy (ipilimumab) for the...
Bristol Myers Squibb application for Opdivo Plus Yervoy for MSI-H/ dMMR colorectal cancer accepted by USFDA Ruchika Sharma27 Feb 2025 12:46 PM ISTBristol Myers Squibb has announced that the U.S. Food and Drug Administration (FDA) has accepted the supplemental biologics license application...
Injectable version of Bristol Myers Squibb cancer drug Opdivo gets USFDA okay Ruchika Sharma28 Dec 2024 12:30 PM ISTOpdivo Qvantig offers a faster delivery for patients to receive this immunotherapy treatment option in three to five minutes compared to 30 minute IV...
Bristol Myers Squibb gets European Commission nod for Opdivo plus Yervoy to treat colorectal cancer Ruchika Sharma25 Dec 2024 4:52 PM ISTPrinceton: Bristol Myers Squibb has announced that the European Commission (EC) has approved Opdivo (nivolumab) plus...
Bristol Myers Squibb gets positive CHMP opinion for Opdivo plus Yervoy to treat adult with MSI-H or dMMR metastatic Colorectal Cancer Ruchika Sharma18 Nov 2024 4:57 PM ISTPrinceton: Bristol Myers Squibb has announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines...
USFDA nod to Perioperative treatment of Neoadjuvant Opdivo, Chemotherapy followed by Surgery, Adjuvant Single Agent Opdivo for Resectable Non Small Cell Lung Cancer Ruchika Sharma5 Oct 2024 1:25 PM ISTPrinceton: Bristol Myers Squibb has announced that the U.S. Food and Drug Administration (FDA) has approved Opdivo (nivolumab) for the...
